{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:40:10Z","timestamp":1768495210052,"version":"3.49.0"},"posted":{"date-parts":[[2021,5,20]]},"group-title":"Immunology","reference-count":78,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,5,21]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Global deployment of vaccines that can provide protection across several age groups is still urgently needed to end the COVID-19 pandemic especially for low- and middle-income countries. While vaccines against SARS-CoV-2 based on mRNA and adenoviral-vector technologies have been rapidly developed, additional practical and scalable SARS-CoV-2 vaccines are needed to meet global demand. In this context, protein subunit vaccines formulated with appropriate adjuvants represent a promising approach to address this urgent need. Receptor-binding domain (RBD) is a key target of neutralizing antibodies (Abs) but is poorly immunogenic. We therefore compared pattern recognition receptor (PRR) agonists, including those activating STING, TLR3, TLR4 and TLR9, alone or formulated with aluminum hydroxide (AH), and benchmarked them to AS01B and AS03-like emulsion-based adjuvants for their potential to enhance RBD immunogenicity in young and aged mice. We found that the AH and CpG adjuvant formulation (AH:CpG) demonstrated the highest enhancement of anti-RBD neutralizing Ab titers in both age groups (\u223c80-fold over AH), and protected aged mice from the SARS-CoV-2 challenge. Notably, AH:CpG-adjuvanted RBD vaccine elicited neutralizing Abs against both wild-type SARS-CoV-2 and B.1.351 variant at serum concentrations comparable to those induced by the authorized mRNA BNT162b2 vaccine. AH:CpG induced similar cytokine and chemokine gene enrichment patterns in the draining lymph nodes of both young adult and aged mice and synergistically enhanced cytokine and chemokine production in human young adult and elderly mononuclear cells. These data support further development of AH:CpG-adjuvanted RBD as an affordable vaccine that may be effective across multiple age groups.<\/jats:p>\n                <jats:sec>\n                  <jats:title>One Sentence Summary<\/jats:title>\n                  <jats:p>Alum and CpG enhance SARS-CoV-2 RBD protective immunity, variant neutralization in aged mice and Th1-polarizing cytokine production by human elder leukocytes.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2021.05.20.444848","type":"posted-content","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T20:30:26Z","timestamp":1621542626000},"source":"Crossref","is-referenced-by-count":9,"title":["Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity"],"prefix":"10.64898","author":[{"given":"Etsuro","family":"Nanishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3651-5167","authenticated-orcid":false,"given":"Timothy R.","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa E.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshine","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyuk-Soo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon D.","family":"van Haren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Brook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann","family":"Diray-Arce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Doss-Gollin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria De","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kijun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Z.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Caradonna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-9954","authenticated-orcid":false,"given":"Jared","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0100-1684","authenticated-orcid":false,"given":"Blake M.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron G.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"Dillen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart M.","family":"Weston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly L.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romana","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Hotez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiquan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirano","family":"Dhe-Paganon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Zanoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al","family":"Ozonoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Frieman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-1945","authenticated-orcid":false,"given":"Ofer","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1095-6156","authenticated-orcid":false,"given":"David J.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2021082320050737000_2021.05.20.444848v2.1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1525"},{"key":"2021082320050737000_2021.05.20.444848v2.2","doi-asserted-by":"crossref","unstructured":"L. R. Baden , H. M. El Sahly , B. Essink , K. Kotloff , S. Frey , R. Novak , D. Diemert , S. A. Spector , N. Rouphael , C. B. Creech , J. McGettigan , S. Kehtan , N. Segall , J. Solis , A. Brosz , C. Fierro , H. Schwartz , K. Neuzil , L. Corey , P. Gilbert , H. Janes , D. Follmann , M. Marovich , J. Mascola , L. Polakowski , J. Ledgerwood , B. S. Graham , H. Bennett , R. Pajon , C. Knightly , B. Leav , W. Deng , H. Zhou , S. Han , M. Ivarsson , J. Miller , T. Zaks , Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine, (2020).","DOI":"10.1056\/NEJMoa2035389"},{"key":"2021082320050737000_2021.05.20.444848v2.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2021082320050737000_2021.05.20.444848v2.4","doi-asserted-by":"crossref","unstructured":"J. Sadoff , M. Le Gars , G. Shukarev , D. Heerwegh , C. Truyers , A. M. de Groot , J. Stoop , S. Tete , W. Van Damme , I. Leroux-Roels , P. J. Berghmans , M. Kimmel , P. Van Damme , J. de Hoon , W. Smith , K. E. Stephenson , S. C. De Rosa , K. W. Cohen , M. J. McElrath , E. Cormier , G. Scheper , D. H. Barouch , J. Hendriks , F. Struyf , M. Douoguih , J. Van Hoof , H. Schuitemaker , Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. The New England journal of medicine, (2021).","DOI":"10.1056\/NEJMoa2034201"},{"key":"2021082320050737000_2021.05.20.444848v2.5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","year":"2020","journal-title":"Nature"},{"key":"2021082320050737000_2021.05.20.444848v2.6","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","year":"2020","journal-title":"The New England journal of medicine"},{"key":"2021082320050737000_2021.05.20.444848v2.7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","year":"2021","journal-title":"Nature"},{"key":"2021082320050737000_2021.05.20.444848v2.8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","year":"2020","journal-title":"Nature"},{"key":"2021082320050737000_2021.05.20.444848v2.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.030"},{"key":"2021082320050737000_2021.05.20.444848v2.10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2103614"},{"key":"2021082320050737000_2021.05.20.444848v2.11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2026920"},{"key":"2021082320050737000_2021.05.20.444848v2.12","doi-asserted-by":"crossref","unstructured":"P. Richmond , L. Hatchuel , M. Dong , B. Ma , B. Hu , I. Smolenov , P. Li , P. Liang , H. H. Han , J. Liang , R. Clemens , Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet (London, England), (2021).","DOI":"10.1016\/S0140-6736(21)00241-5"},{"key":"2021082320050737000_2021.05.20.444848v2.13","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30831-8"},{"key":"2021082320050737000_2021.05.20.444848v2.14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2021082320050737000_2021.05.20.444848v2.15","doi-asserted-by":"crossref","unstructured":"N. C. Kyriakidis , A. L\u00f3pez-Cort\u00e9s , E. V. Gonz\u00e1lez , A. B. Grimaldos , E. O. Prado , SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ vaccines 6, 28 (2021).","DOI":"10.1038\/s41541-021-00292-w"},{"key":"2021082320050737000_2021.05.20.444848v2.16","unstructured":"CTRI. Biological E\u2019s novel Covid-19 vaccine of SARS-CoV-2 for protection against Covid-19 disease., <http:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine> Accessed May 1, 2021"},{"key":"2021082320050737000_2021.05.20.444848v2.17","unstructured":"The New York Times. Coronavirus Vaccine Tracker, <https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html>, Accessed May 3, 2021"},{"key":"2021082320050737000_2021.05.20.444848v2.18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","year":"2020","journal-title":"Nature"},{"key":"2021082320050737000_2021.05.20.444848v2.19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","year":"2020","journal-title":"Cell"},{"key":"2021082320050737000_2021.05.20.444848v2.20","doi-asserted-by":"crossref","unstructured":"L. Premkumar , B. Segovia-Chumbez , R. Jadi , D. R. Martinez , R. Raut , A. Markmann , C. Cornaby , L. Bartelt , S. Weiss , Y. Park , C. E. Edwards , E. Weimer , E. M. Scherer , N. Rouphael , S. Edupuganti , D. Weiskopf , L. V. Tse , Y. J. Hou , D. Margolis , A. Sette , M. H. Collins , J. Schmitz , R. S. Baric , A. M. de Silva , The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 5, (2020).","DOI":"10.1126\/sciimmunol.abc8413"},{"key":"2021082320050737000_2021.05.20.444848v2.21","doi-asserted-by":"crossref","first-page":"105686","DOI":"10.1016\/j.pep.2020.105686","article-title":"Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays","volume":"174","year":"2020","journal-title":"Protein Expr Purif"},{"key":"2021082320050737000_2021.05.20.444848v2.22","doi-asserted-by":"crossref","unstructured":"B. N. C. Dalvie , S. A. Rodriguez-Aponte , B. L. Hartwell , L. H. Tostanoski , A. M. Biedermann , L. E. Crowell , K. Kaur , O. Kumru , L. Carter , J. Yu , A. Chang , K. McMahan , T. Courant , C. Lebas , A. A. Lemnios , K. A. Rodrigues , M. Silva , R. S. Johnston , C. A. Naranjo , M. K. Tracey , J. R. Brady , C. A. Whittaker , D. Yun , S. Kar , M. Porto , M. Lok , H. Andersen , M. G. Lewis , K. R. Love , D. L. Camp , J. M. Silverman , H. Kleanthous , S. B. Joshi , D. B. Volkin , P. M. Dubois , N. Collin , N. P. King , D. H. Barouch , D. J. Irvine , J. C. Love , Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters. bioRxiv, (2021).","DOI":"10.1101\/2021.03.03.433558"},{"key":"2021082320050737000_2021.05.20.444848v2.23","doi-asserted-by":"crossref","unstructured":"S. Yang , Y. Li , L. Dai , J. Wang , P. He , C. Li , X. Fang , C. Wang , X. Zhao , E. Huang , C. Wu , Z. Zhong , F. Wang , X. Duan , S. Tian , L. Wu , Y. Liu , Y. Luo , Z. Chen , F. Li , J. Li , X. Yu , H. Ren , L. Liu , S. Meng , J. Yan , Z. Hu , L. Gao , G. F. Gao , Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis, (2021).","DOI":"10.1016\/S1473-3099(21)00127-4"},{"key":"2021082320050737000_2021.05.20.444848v2.24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS","volume":"182","year":"2020","journal-title":"Cell"},{"key":"2021082320050737000_2021.05.20.444848v2.25","doi-asserted-by":"crossref","unstructured":"B. M. Hauser , M. Sangesland , E. C. Lam , J. Feldman , A. S. Yousif , T. M. Caradonna , A. B. Balazs , D. Lingwood , A. G. Schmidt , Engineered receptor binding domain immunogens elicit pan-coronavirus neutralizing antibodies. bioRxiv, (2020).","DOI":"10.1101\/2020.12.07.415216"},{"key":"2021082320050737000_2021.05.20.444848v2.26","doi-asserted-by":"crossref","unstructured":"T. K. Tan , P. Rijal , R. Rahikainen , A. H. Keeble , L. Schimanski , S. Hussain , R. Harvey , J. W. P. Hayes , J. C. Edwards , R. K. McLean , V. Martini , M. Pedrera , N. Thakur , C. Conceicao , I. Dietrich , H. Shelton , A. Ludi , G. Wilsden , C. Browning , A. K. Zagrajek , D. Bialy , S. Bhat , P. Stevenson-Leggett , P. Hollinghurst , M. Tully , K. Moffat , C. Chiu , R. Waters , A. Gray , M. Azhar , V. Mioulet , J. Newman , A. S. Asfor , A. Burman , S. Crossley , J. A. Hammond , E. Tchilian , B. Charleston , D. Bailey , T. J. Tuthill , S. P. Graham , H. M. E. Duyvesteyn , T. Malinauskas , J. Huo , J. A. Tree , K. R. Buttigieg , R. J. Owens , M. W. Carroll , R. S. Daniels , J. W. McCauley , D. I. Stuart , K. A. Huang , M. Howarth , A. R. Townsend , A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nature communications 12, 542 (2021).","DOI":"10.1101\/2020.08.31.275701"},{"key":"2021082320050737000_2021.05.20.444848v2.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.043"},{"key":"2021082320050737000_2021.05.20.444848v2.28","doi-asserted-by":"crossref","unstructured":"L. Yang , D. Tian , J.-b. Han , W. Fan , Y. Zhang , Y. Li , W. Sun , Y. Wei , X. Tian , D.-d. Yu , X.-l. Feng , G. Cheng , Y.-t. Zheng , Y. Bi , W. Liu , A recombinant receptor-binding domain in trimeric form generates completely protective immunity against SARS-CoV-2 infection in nonhuman primates. bioRxiv, 2021.2003.2030.437647 (2021).","DOI":"10.1101\/2021.03.30.437647"},{"key":"2021082320050737000_2021.05.20.444848v2.29","doi-asserted-by":"crossref","unstructured":"L. He , X. Lin , Y. Wang , C. Abraham , C. Sou , T. Ngo , Y. Zhang , I. A. Wilson , J. Zhu , Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci Adv 7, (2021).","DOI":"10.1126\/sciadv.abf1591"},{"key":"2021082320050737000_2021.05.20.444848v2.30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2020.08.008","article-title":"New horizons in adjuvants for vaccine development","volume":"65","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"2021082320050737000_2021.05.20.444848v2.31","unstructured":"B. Pulendran , S. A. P, D. T. O\u2019Hagan , Emerging concepts in the science of vaccine adjuvants. Nature reviews. Drug discovery, 1\u201322 (2021)."},{"key":"2021082320050737000_2021.05.20.444848v2.32","doi-asserted-by":"crossref","first-page":"101426","DOI":"10.1016\/j.smim.2020.101426","article-title":"The continued advance of vaccine adjuvants - \u2019we can work it out\u2019","volume":"50","year":"2020","journal-title":"Seminars in immunology"},{"key":"2021082320050737000_2021.05.20.444848v2.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"2021082320050737000_2021.05.20.444848v2.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"2021082320050737000_2021.05.20.444848v2.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.050"},{"key":"2021082320050737000_2021.05.20.444848v2.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.11.009"},{"key":"2021082320050737000_2021.05.20.444848v2.37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41467-021-21634-1","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","volume":"12","year":"2021","journal-title":"Nature communications"},{"key":"2021082320050737000_2021.05.20.444848v2.38","doi-asserted-by":"crossref","unstructured":"W. F. Garcia-Beltran , E. C. Lam , K. St Denis , A. D. Nitido , Z. H. Garcia , B. M. Hauser , J. Feldman , M. N. Pavlovic , D. J. Gregory , M. C. Poznansky , A. Sigal , A. G. Schmidt , A. J. Iafrate , V. Naranbhai , A. B. Balazs , Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, (2021).","DOI":"10.1101\/2021.02.14.21251704"},{"key":"2021082320050737000_2021.05.20.444848v2.39","doi-asserted-by":"crossref","unstructured":"A. Kuzmina , Y. Khalaila , O. Voloshin , A. Keren-Naus , L. Boehm-Cohen , Y. Raviv , Y. Shemer-Avni , E. Rosenberg , R. Taube , SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell host & microbe, (2021).","DOI":"10.1101\/2021.02.22.21252002"},{"key":"2021082320050737000_2021.05.20.444848v2.40","doi-asserted-by":"crossref","unstructured":"X. Shen , H. Tang , R. Pajon , G. Smith , G. M. Glenn , W. Shi , B. Korber , D. C. Montefiori , Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. The New England journal of medicine, (2021).","DOI":"10.1056\/NEJMc2103740"},{"key":"2021082320050737000_2021.05.20.444848v2.41","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","year":"2021","journal-title":"Nature"},{"key":"2021082320050737000_2021.05.20.444848v2.42","doi-asserted-by":"crossref","unstructured":"L. J. Abu-Raddad , H. Chemaitelly , A. A. Butt , Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. The New England journal of medicine, (2021).","DOI":"10.1056\/NEJMc2104974"},{"key":"2021082320050737000_2021.05.20.444848v2.43","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3123"},{"key":"2021082320050737000_2021.05.20.444848v2.44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","year":"2021","journal-title":"Nature reviews. Immunology"},{"key":"2021082320050737000_2021.05.20.444848v2.45","doi-asserted-by":"crossref","unstructured":"S. M. Grant , M. Lou , L. Yao , R. N. Germain , A. J. Radtke , The lymph node at a glance - how spatial organization optimizes the immune response. J Cell Sci 133, (2020).","DOI":"10.1242\/jcs.241828"},{"key":"2021082320050737000_2021.05.20.444848v2.46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/imr.12414","article-title":"Dendritic cells in remodeling of lymph nodes during immune responses","volume":"271","year":"2016","journal-title":"Immunol Rev"},{"key":"2021082320050737000_2021.05.20.444848v2.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4"},{"key":"2021082320050737000_2021.05.20.444848v2.48","unstructured":"Centers for Disease Control and Prevention (CDC). COVID-19 Hospitalization and Death by Age, Accessed Apr 3rd, 2021, 2021"},{"key":"2021082320050737000_2021.05.20.444848v2.49","doi-asserted-by":"crossref","first-page":"e0008548","DOI":"10.1371\/journal.pntd.0008548","article-title":"Developing a low-cost and accessible COVID-19 vaccine for global health","volume":"14","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021082320050737000_2021.05.20.444848v2.50","doi-asserted-by":"crossref","unstructured":"K. McMahan , J. Yu , N. B. Mercado , C. Loos , L. H. Tostanoski , A. Chandrashekar , J. Liu , L. Peter , C. Atyeo , A. Zhu , E. A. Bondzie , G. Dagotto , M. S. Gebre , C. Jacob-Dolan , Z. Li , F. Nampanya , S. Patel , L. Pessaint , A. Van Ry , K. Blade , J. Yalley-Ogunro , M. Cabus , R. Brown , A. Cook , E. Teow , H. Andersen , M. G. Lewis , D. A. Lauffenburger , G. Alter , D. H. Barouch , Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature, (2020).","DOI":"10.1038\/s41586-020-03041-6"},{"key":"2021082320050737000_2021.05.20.444848v2.51","doi-asserted-by":"crossref","unstructured":"P. S. Arunachalam , A. C. Walls , N. Golden , C. Atyeo , S. Fischinger , C. Li , P. Aye , M. J. Navarro , L. Lai , V. V. Edara , K. R\u00f6ltgen , K. Rogers , L. Shirreff , D. E. Ferrell , S. Wrenn , D. Pettie , J. C. Kraft , M. C. Miranda , E. Kepl , C. Sydeman , N. Brunette , M. Murphy , B. Fiala , L. Carter , A. G. White , M. Trisal , C.-L. Hsieh , K. Russell-Lodrigue , C. Monjure , J. Dufour , L. Doyle-Meyer , R. B. Bohm , N. J. Maness , C. Roy , J. A. Plante , K. S. Plante , A. Zhu , M. J. Gorman , S. Shin , X. Shen , J. Fontenot , S. Gupta , D. T. O\u2019Hagan , R. V. D. Most , R. Rappuoli , R. L. Coffman , D. Novack , J. S. McLellan , S. Subramaniam , D. Montefiori , S. D. Boyd , J. L. Flynn , G. Alter , F. Villinger , H. Kleanthous , J. Rappaport , M. Suthar , N. P. King , D. Veesler , B. Pulendran , Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv, 2021.2002.2010.430696 (2021).","DOI":"10.1101\/2021.02.10.430696"},{"key":"2021082320050737000_2021.05.20.444848v2.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2021.129893"},{"key":"2021082320050737000_2021.05.20.444848v2.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.061"},{"key":"2021082320050737000_2021.05.20.444848v2.54","doi-asserted-by":"crossref","unstructured":"J. Pollet , W. H. Chen , L. Versteeg , B. Keegan , B. Zhan , J. Wei , Z. Liu , J. Lee , R. Kundu , R. Adhikari , C. Poveda , M. J. Villar , A. C. de Araujo Leao , J. Altieri Rivera , Z. Momin , P. M. Gillespie , J. T. Kimata , U. Strych , P. J. Hotez , M. E. Bottazzi , SARS CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Human vaccines & immunotherapeutics, 1\u201311 (2021).","DOI":"10.1080\/21645515.2021.1901545"},{"key":"2021082320050737000_2021.05.20.444848v2.55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","year":"2009","journal-title":"Lancet (London, England)"},{"key":"2021082320050737000_2021.05.20.444848v2.56","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6445-1_2"},{"key":"2021082320050737000_2021.05.20.444848v2.57","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-004-6244-3"},{"key":"2021082320050737000_2021.05.20.444848v2.58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1189\/jlb.72.3.447","article-title":"CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB\/c mice","volume":"72","year":"2002","journal-title":"Journal of leukocyte biology"},{"key":"2021082320050737000_2021.05.20.444848v2.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.08.016"},{"key":"2021082320050737000_2021.05.20.444848v2.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5565(01)00157-7"},{"key":"2021082320050737000_2021.05.20.444848v2.61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065536"},{"key":"2021082320050737000_2021.05.20.444848v2.62","first-page":"148","article-title":"CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice","volume":"1","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"2021082320050737000_2021.05.20.444848v2.63","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.4.2177-2186.2006"},{"key":"2021082320050737000_2021.05.20.444848v2.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.02.001"},{"key":"2021082320050737000_2021.05.20.444848v2.65","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1016\/j.vaccine.2015.05.070","article-title":"Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"2021082320050737000_2021.05.20.444848v2.66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77077-z"},{"key":"2021082320050737000_2021.05.20.444848v2.67","doi-asserted-by":"crossref","unstructured":"C.-E. Lien , Y.-J. Lin , C. Chen , W.-C. Lian , T.-Y. Kuo , J. D. Campbell , P. Traquina , M.-Y. Lin , L. T.-C. Liu , Y.-S. Chuang , H.-Y. Ko , C.-C. Liao , Y.-H. Chen , J.-T. Jan , C.-P. Sun , Y.-S. Lin , P.-Y. Wu , Y.-C. Wang , M.-H. Tao , Y.-L. Lin , CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. bioRxiv, 2021.2001.2007.425674 (2021).","DOI":"10.1101\/2021.01.07.425674"},{"key":"2021082320050737000_2021.05.20.444848v2.68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG Oligonucleotides as Vaccine Adjuvants","volume":"2197","year":"2021","journal-title":"Methods in molecular biology (Clifton, N.J.)"},{"key":"2021082320050737000_2021.05.20.444848v2.69","first-page":"e91020","article-title":"TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth","volume":"2","year":"2017","journal-title":"JCI insight"},{"key":"2021082320050737000_2021.05.20.444848v2.70","doi-asserted-by":"crossref","unstructured":"C. Garrido , A. D. Curtis , M. Dennis , S. H. Pathak , H. Gao , D. Montefiori , M. Tomai , C. B. Fox , P. A. Kozlowski , T. Scobey , J. E. Munt , M. L. Mallroy , P. T. Saha , M. G. Hudgens , L. C. Lindesmith , R. S. Baric , O. M. Abiona , B. Graham , K. S. Corbett , D. Edwards , A. Carfi , G. Fouda , K. K. A. Van Rompay , K. De Paris , S. R. Permar , SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques. bioRxiv, 2021.2004.2005.438479 (2021).","DOI":"10.1101\/2021.04.05.438479"},{"key":"2021082320050737000_2021.05.20.444848v2.71","doi-asserted-by":"crossref","unstructured":"K. Wu , A. Choi , M. Koch , S. Elbashir , L. Ma , D. Lee , A. Woods , C. Henry , C. Palandjian , A. Hill , J. Quinones , N. Nunna , S. O\u2019Connell , A. B. McDermott , S. Falcone , E. Narayanan , T. Colpitts , H. Bennett , K. Corbett , R. Seder , B. S. Graham , G. B. Stewart-Jones , A. Carfi , D. K. Edwards , Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv, 2021.2004.2013.439482 (2021).","DOI":"10.1101\/2021.04.13.439482"},{"key":"2021082320050737000_2021.05.20.444848v2.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00166-4"},{"key":"2021082320050737000_2021.05.20.444848v2.73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01772"},{"key":"2021082320050737000_2021.05.20.444848v2.74","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2021082320050737000_2021.05.20.444848v2.75","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284"},{"key":"2021082320050737000_2021.05.20.444848v2.76","doi-asserted-by":"crossref","unstructured":"J. Yu , Z. Li , X. He , M. S. Gebre , E. A. Bondzie , H. Wan , C. Jacob-Dolan , D. R. Martinez , J. P. Nkolola , R. S. Baric , D. H. Barouch , Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. Journal of Virology, JVI.00044\u201300021 (2021).","DOI":"10.1128\/JVI.00044-21"},{"key":"2021082320050737000_2021.05.20.444848v2.77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600282"},{"key":"2021082320050737000_2021.05.20.444848v2.78","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.3.476"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.05.20.444848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:44:18Z","timestamp":1768441458000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.05.20.444848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1101\/2021.05.20.444848","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1126\/scitranslmed.abj5305","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,5,20]]},"subtype":"preprint"}}